Juno Therapeutics

What Juno Therapeutics does

Juno Therapeutics is a Seattle-based biotechnology company founded in 2013 that develops CAR-T (Chimeric Antigen Receptor T-cell) immunotherapies for the treatment of cancer. Its core technology engineers a patient's own T-cells to recognize and destroy hematologic cancer cells, with a primary clinical and commercial focus on hematologic malignancies including leukemia and multiple myeloma. Juno has secured FDA approvals for its CAR-T products and is identified alongside 2seventy Bio and Janssen Biotech as a key player in the CAR-T cell therapy market.

Following its 2018 acquisition by Bristol-Myers Squibb, Juno operates as a wholly-owned subsidiary within BMS's cellular therapy franchise. Prior to the acquisition, the company raised over $310 million in venture funding across multiple rounds from ARCH Venture Partners, Alaska Permanent Fund, Bezos Expeditions, and Venrock, and executed a deliberate platform-buildout through acquisitions of AbVitro (~$125M), X BODY ($44M), Stage Cell Therapeutics ($22M), RedoxTherapies, and Contura. The company maintains 501-1000 employees and is supported by BMS's broader oncology pipeline of 50+ compounds across 40+ disease areas as of April 2026.

Juno's business model is a high-touch specialty biotech model: CAR-T therapies are manufactured from patient-derived cells and administered at authorized specialty treatment centers, with per-patient pricing typically in the hundreds of thousands to over one million dollars. Revenue is captured by BMS at the consolidated level and is not separately disclosed, while scientific co-founders including Michel Sadelain, Isabelle Rivière, Stan Riddell, and Lawrence Corey anchor the research capability.

Name

Juno Therapeutics

Website

https://junotherapeutics.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Juno Therapeutics is a Seattle-based biotechnology company, now a wholly-owned Bristol-Myers Squibb subsidiary, that develops FDA-approved CAR-T cell therapies for hematologic malignancies including leukemia and multiple myeloma. It serves patients with blood cancers at authorized specialty treatment centers worldwide.

Ownership category

akta.pro rank

Product category

Cellular Immunotherapy / Oncology Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Cell Therapy Developers (Autologous) (HLAAABAA), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• CAR-T cell therapy
• Cancer immunotherapy
• Cell therapy platform
• Hematologic oncology
• Chimeric antigen receptor

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Core offering

Juno Therapeutics is a clinical-stage biotechnology company that develops cellular immunotherapies, specifically CAR-T (Chimeric Antigen Receptor T-cell) therapies, for the treatment of cancer. The company engineers a patient's own T-cells to recognize and destroy cancer cells, with a primary focus on hematologic malignancies such as leukemia and multiple myeloma. Juno has received FDA approvals for its CAR-T products and operates as a subsidiary of Bristol-Myers Squibb following its 2018 acquisition.

Differentiator

Problem solved

Functional benefit

Products and services

• CAR-T Cell Therapies (FDA-approved portfolio) FDA-approved CAR-T cell therapy products developed by Juno Therapeutics for the treatment of hematologic malignancies including leukemia and multiple myeloma, administered at specialized treatment centers to patients whose conventional therapies have been insufficient.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Adaptimmune: Adaptimmune develops engineered T-cell receptor (TCR-T) therapies, including Tecelra (afami-cel) approved for synovial sarcoma, with a pipeline spanning hematologic and solid tumor indications. It is a direct peer in autologous engineered cell therapy for cancer.
• CRISPR Therapeutics: CRISPR Therapeutics developed Casgevy, the first FDA-approved CRISPR-based gene-edited cell therapy, and has a pipeline of CAR-T candidates. It is a direct peer in engineered cell therapy for hematologic indications and autoimmune disease.
• 2seventy Bio: 2seventy Bio is a cell therapy company that co-developed Abecma (idecabtagene vicleucel), an FDA-approved CAR-T therapy for multiple myeloma, alongside Bristol-Myers Squibb. It is a direct peer as a CAR-T developer targeting the same hematologic malignancies as Juno.
• Allogene Therapeutics: Allogene is a clinical-stage biotechnology company developing allogeneic (off-the-shelf) CAR-T therapies for hematologic malignancies and solid tumors. It is a direct peer in the CAR-T category, targeting overlapping indications with a next-generation modality.

Emerging players

• Caribou Biosciences: Caribou Biosciences is a clinical-stage company developing allogeneic CAR-T cell therapies using CRISPR genome editing for hematologic malignancies and autoimmune diseases. It is an emerging peer in the CAR-T cell therapy space with overlapping indications.
• Precision BioSciences: Precision BioSciences develops allogeneic CAR-T therapies using its ARCUS gene-editing platform for hematologic malignancies and solid tumors. It is an emerging peer in next-generation CAR-T cell therapy targeting overlapping indications.
• Cellectis: Cellectis is a clinical-stage biotechnology company developing allogeneic CAR-T therapies using TALEN gene editing, with candidates in hematologic malignancies. It is an emerging peer in the engineered cell therapy space adjacent to Juno's autologous CAR-T focus.

Broad incumbents

• Novartis: Novartis commercializes Kymriah (tisagenlecleucel), the first FDA-approved CAR-T therapy, for leukemia and lymphoma. It is a broad incumbent competing in the same CAR-T cell therapy space as Juno with an autologous platform.
• Gilead Sciences (Kite Pharma): Kite Pharma, a Gilead subsidiary, develops Yescarta and Tecartus, both FDA-approved CAR-T therapies for hematologic malignancies. It is a broad incumbent in the same CAR-T category as Juno, with overlapping approved indications and similar autologous manufacturing approach.
• Janssen Biotech (Johnson & Johnson): Janssen, in collaboration with Legend Biotech, co-developed Carvykti (ciltacabtagene autoleucel), an FDA-approved CAR-T therapy for multiple myeloma. It is a broad incumbent peer in CAR-T cell therapy alongside Juno.

Market position

Strengths1 record

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/junothera
• Facebookfacebook.com/1711065182492115
• LinkedInlinkedin.com/company/juno-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Juno Therapeutics